Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
Back
Highlighting Key Follicular Lymphoma Data Following ASH 2024
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss key updates in the follicular lymphoma field following the 2024 ASH Annual Meeting
Highlighting Key Follicular Lymphoma Data Following ASH 2024
Episodes
All
All
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for tafasitamab in relapsed/refractory follicular lymphoma.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss their clinical practice experience using tafasitamab in relapsed/refractory DLBCL.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss CD19 expression and the use of tafasitamab in relapsed/refractory DLBCL.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss 2-year follow-up data for liso-cel in relapsed/refractory follicular lymphoma.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for mosunetuzumab in newly diagnosed follicular lymphoma.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss follicular lymphoma data from ASH 2024.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
5